Search results
Showing 1 to 9 of 9 results for donanemab
In development Reference number: GID-TA11221 Expected publication date: TBC
In development Reference number: GID-TA11379 Expected publication date: TBC
Find out what guidance is being considered for development
Technology appraisal and highly specialised technologies appeals
Learn about the NICE Technology Appraisal and Highly Specialised Technologies appeals process, including how decisions are made, the criteria for appeals, and the role of the appeal panel in ensuring fair and transparent evaluations of health technologies.
The benefits from donanemab (also called Kisunla and made by Eli Lilly) and lecanemab (also called Leqembi and made by Eisai) - remain too small to justify the additional cost to the NHS, one of our independent committees has concluded following consultation.
Second consultation launched on NHS funding for Alzheimer's treatments
Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab.
NICE’s methods and processes for evaluating new treatments for use in the NHS are appropriate for the new class of Alzheimer’s drugs but key issues need to be considered, a new report has found.
New Alzheimer's treatment donanemab does not currently demonstrate value for the NHS says NICE
More evidence is needed on the clinical and cost-effectiveness of donanemab, a new treatment for mild Alzheimer’s disease.